Loading…
Hosted by Simon Wentworth · 🇺🇸 US · EN-US · 37 episodes
Established thought leaders with verified media credentials.
The Pharma Letter Podcast provides in-depth discussion and analysis focused on key trends, companies and events in the pharmaceutical and biotech industries. Our guests come from a broad array of sectors and business functions, from early stage research in biopharmaceuticals, to patient engagement and marketing, supply chain management and life sciences investing. Podcasts are typically 20-30 minutes in length and are released approximately once every two weeks.
Simon Wentworth hosts The Pharma Letter Podcast, a news show with 37 episodes published.
This week on The Pharma Letter Podcast, we’re joined by Kenneth Mulvany, founder and executive chair of BenevolentAI: one of the UK’s earliest and most high-profile attempts to apply machine learning to drug discovery. F
This week on The Pharma Letter Podcast, we’re joined by Eron Kelly, chief executive of ConcertAI: a company applying artificial intelligence to accelerate oncology research and clinical development. ConcertAI sits at the
This week on the Podcast, we are joined by Dr Amr Hanbali. During Blood Cancer Awareness Month, Guy Martin, news editor at The Pharma Letter, sat down with Dr Hanbali to discuss his experiences treating patients with CAR
This week on The Pharma Letter Podcast, we’re joined by Marina Udier, chief executive of Nouscom — a biotech company developing cancer vaccines. Founded in 2015, the firm is working on cancer vaccines that use a viral ve
This week on The Pharma Letter Podcast, we’re joined by Howard Fillit, co-founder and chief science officer at the Alzheimer’s Drug Discovery Foundation (ADDF). As the FDA approval of anti-amyloid drugs like lecanemab an
This week on The Pharma Letter Podcast, we’re joined by Quin Wills, co-founder and chief scientific officer of UK biotech Ochre Bio. A physician-scientist with a background in genomics and computational biology, Quin has
This week on The Pharma Letter Podcast, we are joined by Tony Clarke, senior VP of IT digital operations at ICON (Nasdaq: ICLR). As a leader in digital transformation within clinical research, Tony has been at the forefr
In this week’s podcast, we welcome Iddo Peleg, CEO and co-founder of Yonalink, who provides insights into the current and future state of the clinical trial industry. As we move headlong into 2025, a year that appears se
In this episode, we’ll take a look at the role of Japanese pharmaceutical groups in the UK, with Jackie Davis, general manager at Astellas Pharma. Tokyo-headquartered Astellas (TYO: 4503) has developed a strong portfolio
This week, we discuss a novel AI-driven approach to drug development, and its potential to transform the treatment of cancer and autoimmune diseases. We are joined by Yanay Ofran, chief executive and founder of Israel-ba
This week we’re focusing on an area of clinical research that has been of great interest for a number of years, that is NASH, also known as MASH. It’s a high area of unmet medical need, with over 20 million diagnosed cas
This week we are speaking with the chief executive of British drug development company Ellipses Pharma. Founded in 2018 to create new cancer therapies, the firm is following a unique multimodal approach to clinical devel
In the world of outsourced clinical research, ICON is a big fish in a pond full of other increasingly big fish. In this episode of The Pharma Letter Podcast, we chat with the company’s chief commercial officer, George Mc
With an Accelerated nod for Aduhelm (aducanumab) and now full approval for Leqembi (lecanemab) in the USA, Biogen (Nasdaq: BIIB) and Eisai (TYO: 4523) have overturned decades of failure in Alzheimer’s. But at the annual
In the runup to the annual meeting of the Alzheimer’s Association, this week we are speaking with Michael Irizarry, deputy chief clinical officer at Eisai US. At the event in July, there will be plenty to discuss, with r
Set against a backdrop of foundering confidence in biotech stocks, the success of some companies incubated by Massachusetts-based Flagship Pioneering has been remarkable. Flagship has invested billions of dollars getting
A draft of the European Commission’s ongoing review of pharmaceutical legislation has leaked, prompting a bitterly-worded reaction from drugmakers, which accuse legislators of “sabotaging” the industry. There is no doubt
This week on The Pharma Letter Podcast, we are joined by Galapagos (Euronext: GLPG) chief executive Paul Stoffels. After an illustrious career as chief scientific officer at Johnson & Johnson (NYSE: JNJ), Dr Stoffels is
The outcome of the recent midterm elections in the USA surprised many by returning a Democrat-led Senate, preventing Republicans from gaining control of the next Congress. Analysts, having expected a stronger showing for
*Partnered content In Boston, Massachusetts, one company is now making significant headway in the development of an innovative treatment for rare pediatric liver diseases. Led by president and chief executive officer Ron
Sponsor detection runs nightly. Check back soon.
No public pitch examples yet for this show.
Generate your own personalised pitchBased on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:
Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
To pitch The Pharma Letter Podcast, visit http://www.thepharmaletter.com for contact information, then craft a tight one-paragraph hook that ties your expertise to a gap in their recent news coverage.
The Pharma Letter Podcast is hosted by Simon Wentworth. The show is categorised under news and has published 37 episodes.
The Pharma Letter Podcast has published 37 episodes.
The Pharma Letter Podcast regularly covers news. It sits in the news category.
The Pharma Letter Podcast is accessible for guests with genuine news expertise. A personalised, episode-aware pitch will still outperform a generic one every time.
The Pharma Letter Podcast hasn't explicitly signalled guest openness in recent episodes. That doesn't rule out pitching. your hook just needs to be especially compelling and relevant to their recent content.
Episodes of The Pharma Letter Podcast average 20 minutes. a focused format where a clear narrative arc and tight preparation matter most.
Our data rates The Pharma Letter Podcast's guest bar at 80/100 (Premium tier). Established thought leaders with verified media credentials. Sign in to PitchCentric to see how your own Pod Score compares against this show.
Methodology. Booking Probability™ blends Listen Score, 30-day Virality, open-to-guests detection, and Apple ratings. Data refreshed every 60 minutes. Listen Score and Booking Probability are calculated by PitchCentric. Last enriched 6 days ago.